View our latest presentation! Last week, Andreas represented Stayble Therapeutics at the Redeye Investor Forum. During the presentation, Andreas provided a detailed update on our latest developments and outlined the forthcoming plans and objectives….
Read moreStayble presented at Financial Stockholm’s investor meeting at Scandic Anglais in Stockholm, 25th of September. Our CEO, Andreas Gerward, shared insights about the Company’s latest progress, future plans, and how…
Read moreIn the April 2021 edition, CEO Andreas Gerward, discusses the ongoing clinical phase 2b, the recruitment of Sara Richardson in the newly created role VP CMC & Regulatory Affairs and…
Read moreIn the February 2021 edition, CEO Andreas Gerward, discusses the oversubscribed rights issue, next steps and partnering activities. Inside Stayble is a communication channel aiming to provide shareholders with monthly…
Read moreIn the January 2021 edition, CEO Andreas Gerward, gives a status report from the ongoing Phase 2b trial, current partnering activities and the upcoming rights issue. Inside Stayble is a…
Read moreIn the December 2020 edition, CEO Andreas Gerward, explains the upcoming rights issue more in-depth and reflects over 2020 and the upcoming 2021. Inside Stayble is a new communication channel…
Read moreIn the November 2020 edition, CEO Andreas Gerward, explains the clinical phase IIb study with STA363 more in-depth and provides an overview of the company’s current affairs. Inside Stayble is a new communication channel aiming…
Read moreSee CEO Andreas Gerward present at BioStock Life Science Summit 2020
Read moreIn the October 2020 edition, CEO Andreas Gerward, covers the progress of the clinical phase IIb study with STA363, importance of participating in Eurospine congress, recruitment process of a CCO,…
Read moreListen to CEO Andreas Gerward´s presentation at LSX Nordic Congress Virtual 2020.
Read more
